What factors are driving the United States to increase scrutiny of China's biotechnology sector, according to a recent GlobalData report highlighting China's emergence as a global biotech innovation hub and the related concerns over pharmaceutical supply-chain resilience, economi

2. Pharmaceutical Supply-Chain Resilience

• An estimated 60% of U.S. generic medications have an active ingredient originating from China . China is the sole source supplier for at least one key starting material (KSM) in over 700 different active pharmaceutical ingredients (APIs), and has surpassed India as the foremost producer of essential pharmaceutical ingredients .
• This creates an acute dependency risk, which the COVID-19 pandemic exposed and policymakers are now moving to address through legislation like the Biosecure Act (banning U.S. government procurement from Chinese firms such as BGI Genomics, Wuxi Apptec, and Wuxi Biologics) .

3. Economic Competitiveness & Innovation Shift

• China-to-West licensing value hit a record $41.5 billion in 2024 (up 66% year-on-year), with Big Pharma sourcing 28% of all innovative assets from China .
• One-third of all biotech assets licensed by Big Pharma globally in 2024 originated in China, up from less than 10% in 2017 . In oncology alone, China commanded $30 billion in licensing deals in 2024, tripling U.S. output .
• China's global share of clinical trials for the most innovative drugs increased sixfold from 2016 to 2025, reaching 30%, while the U.S. share fell from 45% to 33% . China now accounts for 7,141 drugs (31.1%) of the global drug pipeline .

4. Heavy State Support & Trade Concerns

• The U.S. International Trade Commission (USITC) launched a formal factfinding investigation in February 2026 to examine Chinese state support and pricing practices in the biotechnology sector .
• The Biosecure Act (first presented May 2024) and the proposed Biotechnology Innovation and Security Act (BINSA) (introduced June 2026) are legislative tools seeking to restrict U.S.-China biotech ties on national security grounds .

In short, the driving forces are: China's rapid emergence as a genuine innovation hub (no longer just a manufacturing base) ; deep U.S. reliance on Chinese drug ingredients; China's growing share of early-stage drug R&D; and Beijing's use of state subsidies, which together have triggered a bipartisan national-security-driven push to decouple, restrict procurement, and boost domestic resilience.